Article preview from IN VIVO - February, 2013
CMS held its annual new-technology Town Hall February 5, hearing from applicants for a drug-eluting peripheral artery stent, a neurostimulator system for epilepsy seizures, a transcatheter mitral valve repair system and a retinal prosthesis system.
Article preview from IN VIVO - February, 2013
Four device companies seeking Medicare hospital inpatient new-technology add-on payments for fiscal 2014 made pitches to CMS February 5 on how their technologies represent a substantial clinical improvement.
CMS held its annual new-technology Town Hall at its Baltimore headquarters to hear presentations from Cook Medical Inc. for its Zilver PTX drug-eluting peripheral artery stent; NeuroPace Inc. for its RNS responsive neurostimulation system for epilepsy seizures; Abbott Vascular Devicesfor its MitraClip transcatheter mitral valve repair system; and Second Sight Medical Products Inc. for its ArgusII retinal prosthesis system.
Pharmaceutical company CSL Behring had also submitted a new-tech add-on application for its Four-Factor Prothrombin Complex Concentrate (Human) (4F-PCC), a replacement therapy for patients with an acquired coagulation factor deficiency due to warfarin and who are experiencing severe bleeding. But the firm did not make a presentation at the Town Hall.
Continued...
Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.
Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512
Comments